Dyslipidemias in patients taking statins Nutritional, Metabolic, Endocrine
Conditions
Interventions
The first part of the study will consist of 15-17 semi-structured interviews with patients. Under-researched populations will be targeted to identify key determinants across diverse groups of patients
Sponsors
Imperial College London
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: Patients: 1. Have been prescribed statins 2. 18+ years old Health professionals: 1. Clinical pharmacists, General Practitioners (GPs), practice nurses or healthcare assistants 2. Regularly prescribe statins, or consult with, or advise patients on their statin therapy
Exclusion criteria
Exclusion criteria: Patients: 1. Age >18 years old 2. Pregnant women 3. Patients who have never been prescribed statins 4. Cognitive impairment 5. Severe life-limiting condition 6. Did not speak English if a translator cannot be arranged for them 7. Did not consent to participate Health professionals 1. Working only on secondary care 2. Without experience in prescribing statins, managing, or advising patients on following statin therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcomes as of 03/06/2026: 1. Modifiable factors (barriers and facilitators) affecting adherence to statin medications measured using interviews based on Theoretical Domains Framework 2. Acceptability of intervention measured by focus groups based on Theoretical Framework of Acceptability and a questionnaire at user testing 3. Usability and engagement of intervention measured using self-developed questionnaire at user testing Previous primary outcomes: 1. Modifiable factors (barriers and facilitators) affecting adherence to statin medications measured using interviews based on Theoretical Domains Framework 2. Acceptability of intervention measured by focus groups based on Theoretical Framework of Acceptability at user testing 3. Usability of intervention measured using the System Usability Scale (SUS) questionnaire at user testing 4. Intervention engagement measured using digital log files at user testing | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Key statin adherence modifiable factors for different groups of patients measured by interviews 2. Self-reported statin adherence measured using the 3 item Likert scale from Voils 2012 at recruitment 3. Sociodemographic characteristics measured by pre-screening questionnaire at recruitment | — |
Countries
England, United Kingdom
Contacts
Public ContactJaviera Rosenberg
Outcome results
None listed